Share

    


Overview

As the role of immunotherapies in treating patients with renal cell carcinoma (RCC) grows, keeping up with the pace of emerging data on combination therapy regimens, effective practices for monitoring and managing immune-related adverse events, and educating patients to empower informed decision-making can be challenging.

This CME, CNE, and CPE-accredited educational program is designed to provide all members of the multidisciplinary care team knowledge and resources to successfully address practical issues and barriers faced in integration of immunotherapies into the treatment of renal cell carcinoma (RCC).

The program will be presented in two formats: a live, on-site learning workshop and an audio-guided online course.

Online Course

This initiative aims to provide guidance to the multidisciplinary cancer care team on the practical issues and barriers associated with incorporating immunotherapies in the treatment of RCC in the community setting. This initiative will review the rationale for combining immunotherapies with an angiogenesis inhibitor, vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR TKI), optimal drug combinations, sequencing of therapies, patient selection criteria and monitoring and managing immune-related adverse events (irAEs) in patients with RCC.
Learn More & Register

Live Workshops

ACCC Cancer Program members have an opportunity to host a live, half-day workshop onsite at their institution.

At the live workshops, a three-member multidisciplinary expert faculty panel will provide both didactic presentations and collaborative open discussion with members of the multidisciplinary care team. Topics covered include, but are not limited to, a review of the rationale for using immunotherapies and immunotherapy combinations, optimal sequencing of therapies, patient selection criteria, and monitoring and managing immune-related adverse events (irAEs) in patients with metastatic RCC. Collateral issues discussed include coordination and communication within the multidisciplinary care team, coverage and reimbursement, and fostering patient education and engagement.

During the workshop, participants will use the Institute for Healthcare Improvement's Plan-Do-Study-Act tool to develop a customized action plan.  Workshop sites will report on their progress at 3 and 6 months post-participation.

If your program is interested in hosting this educational program, please contact Mary Stanley, Project Manager, at mstanley@accc-cancer.org.

 

Last year, ACCC successfully implemented collaborative learning workshops in IO. The participating sites were successful in implementing 100% of the items listed on the PDSA action plans within 6 months of participating in the workshops. The results from initiative were presented at the 2019 ASCO Annual Conference.
View Presentation

Jointly Provided By:

AXIS Medical Education Logo
accclogo_hires-300x78 

Supporter

This activity is supported by educational grants from Eisai, EMD Serono, and Pfizer.